News

The U.S. Food and Drug Administration (FDA) granted orphan drug status to Polaryx Therapeutics’ PLX-200 in response to a lack of treatments available for late infantile neuronal ceroid lipofuscinosis (LINCL), a type of Batten disease. PLX-200 is a repurposed drug (one that was developed for one indication…

Researchers studying the loss of the CLN5 protein, which causes Batten disease, found that it leads to the reduced production of new fully functional neurons. It also increased neuronal inflammation in mouse models of the neurodegenerative disorder. The study, “Loss of CLN5 causes altered neurogenesis in a childhood neurodegenerative…